← Russell 3000 cross-section

ASTH Astrana Health, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Industrials

Scale

Market cap
$1.9bn
Revenue TTM
$3.8bn
Net income TTM
$40m
Free cash flow
$94m
Composite score
44.2
Sector rank
#1669

Valuation

P / E
46.9
EV / EBITDA
14.6
EV / sales
0.6
FCF yield
4.96%
Earnings yield vs 10-yr
-2.60pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
1.1%
EBITDA margin
4.2%
ROE
4.9%
ROIC
7.7%
Revenue growth
58.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue Revenue for the three months ended June 30, 2026 was $972.5 million, as compared to $654.8 million for the three months ended June 30, 2025, an increase of $317.7 million or 49%. The increase in revenue was primarily attributable to the Prospect acquisition, which contributed $281.5 million of revenue. In addition, capitation revenue increased by $45.0 million primarily as a result of enrollees transitioning to full risk through our Restricted Knox-Keene plans. Revenue for the six months ended June 30, 2026 was $1,937.6 million, as compared to $1,275.2 million for the six months ended June 30, 2025, an increase of $662.4 million or 52%. …Astrana Health, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →